Antimicrobial Agents and Chemotherapy, September 2000, p. 2349-2355, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
andPublic Health Research Institute, New York, New York 10016
Received 1 February 2000/Returned for modification 4 May 2000/Accepted 8 June 2000
The Cryptococcus neoformans PMA1 gene, encoding a
plasma membrane H+-ATPase, was isolated from a genomic DNA
library of serotype A strain ATCC 6352. An open reading frame of 3,380 nucleotides contains six introns and encodes a predicted protein
consisting of 998 amino acids with a molecular mass of approximately
108 kDa. Plasma membranes were isolated, and the H+-ATPase
was shown by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
to be slightly larger than the S. cerevisiae
H+-ATPase, consistent with its predicted molecular mass.
The plasma membrane-bound enzyme exhibited a pH 6.5 optimum for ATP
hydrolysis, Km and Vmax
values of 0.5 mM and 3.1 µmol mg
1 min
1,
respectively, and an apparent Ki for vanadate
inhibition of 1.6 µM. ATP hydrolysis in plasma membranes and medium
acidification by whole cells were inhibited by ebselen, a nonspecific
H+-ATPase antagonist which was also fungicidal. The
predicted C. neoformans protein is 35% identical to proton
pumps of both pathogenic and nonpathogenic fungi but exhibits more than
50% identity to PMA1 genes from plants. Collectively, this
study provides the basis for establishing the Cryptococcus
H+-ATPase as a viable target for antifungal drug discovery.
Present address: Laboratory of Molecular Cell Biology, K. U. Leuven, Leuven, Belgium.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |